The National Comprehensive Cancer Network (NCCN) has announced a guideline update concerning the treatment of patients with acute lymphoblastic leukemia (ALL), B-cell lymphomas, pediatric ALL, and pediatric aggressive mature B-cell lymphoma.1
SERB SAS` Voraxaze (glucarpidase) Receives Approval in Europe
LONDON, Nov. 30, 2021n/PRNewswire/ -- SERB and BTG Specialty Pharmaceuticals today announced nthat the Committee for Medicinal Products for Human Use (CHMP) of the nEuropean Medicines Agency (EMA) adopted a positive opinion recommending a marketing authorisation for Voraxaze®n(glucarpidase) to reduce toxic plasma methotrexate concentration in nadults and children (aged 28 days and older) with delayed methotrexate nelimination or at risk of methotrexate toxicity.
MONTREAL, Nov. 12, 2020 /PRNewswire/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FRANKFURT: VP2), a Canadian pharmaceutical company, announced today that it has recently received a Notice of Compliance from Health Canada granting market authorization for Amikacin, an antibiotic used within the hospital setting. Valeo also announced that shipments of Ethacrynate Sodium have commenced in the U.S. market.
LONDON, Aug. 17, 2020 /PRNewswire/ -- BTG Specialty Pharmaceuticals, a division of Boston Scientific (NYSE:BSX), today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorisation Application (MAA) for Voraxaze® (glucarpidase). BTG Specialty Pharmaceuticals is seeking marketing authorization of Voraxaze® for the treatment of adults and children (from 28 days of age) at risk of methotrexate toxicity due to delayed methotrexate elimination.
PHILADELPHIA, April 23, 2020 /PRNewswire/ -- Initial data has been posted online from an investigator initiated pilot study exploring the planned use of Voraxaze® (glucarpidase) administered with repeated doses of methotrexate and rituximab in patients with central nervous system lymphoma (CNSL). Researchers at the Memorial Sloan Kettering Cancer Center planned to present their findings at an American Academy of Neurology (AAN) meeting in April which had to be cancelled. The abstract is available on the AAN website here.
BTG International's Voraxaze (Glucarpidase) Receives Supplemental Approval in US